- Home
- GIGM vs JUNS Comparison
GIGM vs JUNS Comparison
Compare GIGM & JUNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- JUNS
- Stock Information
- Founded
- GIGM 1998
- JUNS 2015
- Country
- GIGM Taiwan
- JUNS United States
- Employees
- GIGM N/A
- JUNS N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- JUNS
- Sector
- GIGM Technology
- JUNS
- Exchange
- GIGM Nasdaq
- JUNS NYSE
- Market Cap
- GIGM 16.1M
- JUNS 20.5M
- IPO Year
- GIGM 2000
- JUNS 2024
- Fundamental
- Price
- GIGM $1.43
- JUNS $1.42
- Analyst Decision
- GIGM
- JUNS
- Analyst Count
- GIGM 0
- JUNS 0
- Target Price
- GIGM N/A
- JUNS N/A
- AVG Volume (30 Days)
- GIGM 6.7K
- JUNS 734.6K
- Earning Date
- GIGM 08-12-2025
- JUNS 08-11-2025
- Dividend Yield
- GIGM N/A
- JUNS N/A
- EPS Growth
- GIGM N/A
- JUNS N/A
- EPS
- GIGM N/A
- JUNS N/A
- Revenue
- GIGM $3,103,000.00
- JUNS N/A
- Revenue This Year
- GIGM N/A
- JUNS N/A
- Revenue Next Year
- GIGM N/A
- JUNS $6,418.21
- P/E Ratio
- GIGM N/A
- JUNS N/A
- Revenue Growth
- GIGM N/A
- JUNS N/A
- 52 Week Low
- GIGM $1.28
- JUNS $0.51
- 52 Week High
- GIGM $1.80
- JUNS $19.51
- Technical
- Relative Strength Index (RSI)
- GIGM 46.68
- JUNS N/A
- Support Level
- GIGM $1.40
- JUNS N/A
- Resistance Level
- GIGM $1.48
- JUNS N/A
- Average True Range (ATR)
- GIGM 0.05
- JUNS 0.00
- MACD
- GIGM 0.00
- JUNS 0.00
- Stochastic Oscillator
- GIGM 18.87
- JUNS 0.00
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.